相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Systematic review: colitis associated with anti-CTLA-4 therapy
A. Gupta et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
Troy Z. Horvat et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
Dirk Schadendorf et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
What's new in melanoma? Combination!
Paolo A. Ascierto et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2015)
Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients
Saif S. Ahmad et al.
MELANOMA RESEARCH (2015)
Ipilimumab-induced colitis in patients with metastatic melanoma
Kara M. De Felice et al.
MELANOMA RESEARCH (2015)
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Ipilimumab-induced hypophysitis: review of the literature
P. B. Araujo et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2015)
Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy
Nicola Mozzillo et al.
ONCOIMMUNOLOGY (2015)
Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis
A Doran Bostwick et al.
Journal for ImmunoTherapy of Cancer (2015)
Systemic High-Dose Corticosteroid Treatment Does Not Improve the Outcome of Ipilimumab-Related Hypophysitis: A Retrospective Cohort Study
Le Min et al.
CLINICAL CANCER RESEARCH (2015)
Ipilimumab in Melanoma Patients with Brain Metastasis: A Retrospective Multicentre Evaluation of Thirty-eight Patients
Maria-Polina Konstantinou et al.
ACTA DERMATO-VENEREOLOGICA (2014)
Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution
Mabel Ryder et al.
ENDOCRINE-RELATED CANCER (2014)
Ipilimumab-Induced Hypophysitis: A Detailed Longitudinal Analysis in a Large Cohort of Patients With Metastatic Melanoma
Alexander T. Faje et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L. Topalian et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Ipilimumab in patients with cancer and the management of dermatologic adverse events
Mario E. Lacouture et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2014)
The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014
Paolo A. Ascierto et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2014)
Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort
Paolo A. Ascierto et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2014)
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Caroline Robert et al.
LANCET (2014)
Mitigating the toxic effects of anticancer immunotherapy
Tara C. Gangadhar et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
Ipilimumab for advanced melanoma: experience from the Spanish Expanded Access Program
Alfonso Berrocal et al.
MELANOMA RESEARCH (2014)
Ipilimumab in the treatment of metastatic melanoma: management of adverse events
Giuseppina Della Vittoria Scarpati et al.
ONCOTARGETS AND THERAPY (2014)
Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial
M. Reck et al.
ANNALS OF ONCOLOGY (2013)
Molecular Pathways: Coexpression of Immune Checkpoint Molecules: Signaling Pathways and Implications for Cancer Immunotherapy
Christopher J. Nirschl et al.
CLINICAL CANCER RESEARCH (2013)
Efficacy and Safety of Retreatment with Ipilimumab in Patients with Pretreated Advanced Melanoma Who Progressed after Initially Achieving Disease Control
Caroline Robert et al.
CLINICAL CANCER RESEARCH (2013)
Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies
Yannick Bulliard et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery
Maya Mathew et al.
MELANOMA RESEARCH (2013)
Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Omid Hamid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Hepatotoxicity with Combination of Vemurafenib and Ipilimumab
Antoni Ribas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells
Mark J. Selby et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Concurrent Radiotherapy and Ipilimumab Immunotherapy for Patients with Melanoma
Christopher A. Barker et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Ipilimumab and radiation therapy for melanoma brain metastases
Ann W. Silk et al.
CANCER MEDICINE (2013)
ASSOCIATION OF IPILIMUMAB THERAPY FOR ADVANCED MELANOMA WITH SECONDARY ADRENAL INSUFFICIENCY: A CASE SERIES
Le Min et al.
ENDOCRINE PRACTICE (2012)
Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non-Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
Thomas J. Lynch et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival Clinical article
Jonathan P. S. Knisely et al.
JOURNAL OF NEUROSURGERY (2012)
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial
Anna Maria Di Giacomo et al.
LANCET ONCOLOGY (2012)
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
Kim Margolin et al.
LANCET ONCOLOGY (2012)
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
Evan J. Lipson et al.
CLINICAL CANCER RESEARCH (2011)
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma
Evan M. Hersh et al.
INVESTIGATIONAL NEW DRUGS (2011)
Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial
Jeffrey S. Weber et al.
MELANOMA RESEARCH (2011)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study
S. J. O'Day et al.
ANNALS OF ONCOLOGY (2010)
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
Jedd D. Wolchok et al.
LANCET ONCOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Development of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy
Axel Hoos et al.
SEMINARS IN ONCOLOGY (2010)
Phase I Study of Ipilimumab, an Anti-CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma
Stephen M. Ansell et al.
CLINICAL CANCER RESEARCH (2009)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
Jeffrey Weber et al.
CLINICAL CANCER RESEARCH (2009)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
CD28 and CTLA-4 coreceptor expression and signal transduction
Christopher E. Rudd et al.
IMMUNOLOGICAL REVIEWS (2009)
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies
Karl S. Peggs et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
CTLA-4 control over Foxp3+ regulatory T cell function
Kajsa Wing et al.
SCIENCE (2008)
Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade
Stephanie G. Downey et al.
CLINICAL CANCER RESEARCH (2007)
Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis
James C. Yang et al.
JOURNAL OF IMMUNOTHERAPY (2007)
Melanocytic Nevi and sun exposure in a cohort of Colorado children: Anatomic distribution and site-specific sunburn
Athena T. Dodd et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2007)
A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer
Eric J. Small et al.
CLINICAL CANCER RESEARCH (2007)
Standard operating procedures of the electrochemotherapy:: Instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the Cliniporator™ by means of invasive or non-invasive electrodes
Lluis M. Mir et al.
EJC SUPPLEMENTS (2006)
Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma
AV Maker et al.
JOURNAL OF IMMUNOTHERAPY (2006)
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4
Kimberly E. Beck et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: A phase I/II study
AV Maker et al.
ANNALS OF SURGICAL ONCOLOGY (2005)
Cytotoxic T-Lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer
JA Blansfield et al.
JOURNAL OF IMMUNOTHERAPY (2005)
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4
P Attia et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Relationship between time interval from primary surgery to the start of taxane- plus platinum-based chemotherapy and clinical outcome of patients with advanced epithelial ovarian cancer: Results of a multicenter retrospective Italian study
A Gadducci et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity
LP Chen
NATURE REVIEWS IMMUNOLOGY (2004)
CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems
PD Gregor et al.
VACCINE (2004)
Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques
T Keler et al.
JOURNAL OF IMMUNOLOGY (2003)
Cutting edge: Transplantation tolerance through enhanced CTLA-4 expression
C Ariyan et al.
JOURNAL OF IMMUNOLOGY (2003)
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
GQ Phan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Melanoma etiology: where are we?
MA Tucker et al.
ONCOGENE (2003)
Negative co-receptors on lymphocytes
RJ Greenwald et al.
CURRENT OPINION IN IMMUNOLOGY (2002)
Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25+CD4+ regulatory cells that control intestinal inflammation
S Read et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of Intergroup Trial E1690/S9111/C9190
JM Kirkwood et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
分享论文
